Anzeige
Mehr »
Dienstag, 30.06.2026 - Börsentäglich über 12.000 News
China kontrolliert Seltene Erden - Brasilien könnte die Antwort sein
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
1.045 Leser
Artikel bewerten:
(2)

Speechmatics Limited: AI can now understand health signals from 15 seconds of your voice, including type 2 diabetes, fatigue and stress

CAMBRIDGE, United Kingdom and SAN FRANCISCO, April 16, 2026 (GLOBE NEWSWIRE) -- Speechmatics and thymia are combining medical-grade speech-to-text with clinical-grade voice biomarker intelligence to identify health signals carried in every voice conversation.

Their joint platform identifies 30-plus health signals from 15 seconds of natural speech, including stress, fatigue, depression and anxiety symptoms, type 2 diabetes and driver impairment, then acts on them in real time.

Delivered through a single integration, the offering returns health signals alongside standard transcription at over 85% accuracy. No additional hardware is needed.

15 seconds of audio, 30 health signals

thymia's technology processes audio at 15-second intervals through a single integration, reading neurological signatures across both acoustic and linguistic patterns to extract health signals from natural speech.

Built on the largest dataset of its kind, including 75,000+ unique voices measured over time, thymia's science is validated in 20-plus peer-reviewed publications including Nature Scientific Reports. Its contextual interpreter then translates those signals into actionable recommendations.

Speechmatics' speech engine, trained on millions of hours of audio, handles accuracy across accented speech and non-native speakers. That breadth matters: a technology like this, deployed at population scale, has to work equally well regardless of how someone speaks.

"thymia has built something that turns an everyday voice interaction into actionable health insights. Our job is to make sure that works for everyone who speaks, not just the people whose voices AI has historically been built around. That's the version of this technology worth building." - Katy Wigdahl, CEO, Speechmatics

A $5 billion market and a July 2026 EU mandate

Six years of research and development underpin thymia's technology, with research published in Nature Scientific Reports. Built on rigorous science, one of the largest and most diverse datasets of its kind, and safety-first design, the company is now pursuing medical device regulatory approvals - the final validation of a technology already trusted in safety-critical industries.

Beyond healthcare, thymia's technology is already deployed in safety-critical industries including automotive, with applications spanning voice AI agents, contact centres and telecoms. Technology like thymia's is fast becoming essential: the EU mandates driver fatigue monitoring in all new vehicles by July 2026, and the voice biomarker market is projected to reach $5 billion by 2028.

"Until now, no technology could read the complete signal carried in a voice conversation, at scale. Together with Speechmatics, we combine medical-grade speech-to-text with clinical-grade voice biomarker intelligence, understanding not just what is said but how the human saying it actually is." - Emilia Molimpakis, CEO & Co-founder, thymia

Launching at Voice AI Space

The partnership will be launched this weekend at THE VOICE AI HACK, a hackathon centered on medical applications of voice AI. Developers and healthcare innovators are invited to build on the combined Speechmatics-thymia platform. Register at luma.com/voiceaihack.

About Speechmatics
Speechmatics is the Voice AI company on a mission to understand every voice. Its speech-to-text technology delivers industry-leading accuracy across 55+ languages, with specialized models for healthcare, media, contact centers, and enterprise organizations worldwide. Speechmatics powers leading technology providers including Adobe, AI Media, Content Guru, and Nordhealth, and offers deployment across cloud, on-prem, and on-device. www.speechmatics.com.

About thymia
thymia is the human state voice intelligence company. Its technology reads the complete signal carried in voice, detecting 30+ clinical-grade biomarkers from just 15 seconds of speech, and acts on it in real time, delivering safety and experience value to partners. Built on one of the largest datasets of its kind, including 75,000+ unique voices, thymia is trusted across healthcare, safety-critical industries and beyond. Learn more at thymia.ai

Media contact: Mieke Smith, Speechmatics: mieke.smith@speechmatics.com
Stella Lempidaki, thymia: nfo@thymia.ai


© 2026 GlobeNewswire (Europe)
SpaceX-Hype zu teuer – Diese 5 Aktien bieten bessere Chancen
Raumfahrt-Aktien gehören aktuell zu den heißesten Wetten an den Börsen. Spätestens mit dem spektakulären Börsengang von SpaceX ist der Sektor endgültig im Fokus der Anleger angekommen. Fantasien rund um Satellitenkommunikation, Rechenzentren im All und neue Geschäftsmodelle treiben die Kurse immer weiter nach oben.

Doch während die Begeisterung steigt, werden auch die Risiken größer. Viele Space-Start-ups sind inzwischen extrem hoch bewertet, arbeiten noch nicht profitabel und hängen stark von stetigem Kapitalzufluss ab. Schon kleine Rückschläge könnten die ambitionierten Wachstumspläne ins Wanken bringen.

Für Anleger, die vom Boom der Raumfahrt profitieren wollen, lohnt sich daher ein Perspektivwechsel. Statt auf überhitzte Pure Plays zu setzen, rücken etablierte Konzerne in den Fokus – Unternehmen mit jahrzehntelanger Erfahrung, stabilen Cashflows und engen Verbindungen zu Raumfahrtagenturen wie NASA und ESA.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau dieses Profil erfüllen: solide bewertet, operativ stark und bestens positioniert, um langfristig vom Space-Boom zu profitieren.

Jetzt den kostenlosen Report sichern – bevor der Markt die versteckten Gewinner entdeckt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.